The interferon paradox: Can inhibiting an antiviral mechanism advance an HIV cure?

Journal of Clinical Investigation

Volumn 127, Issue 1, 2017, Pages 103-105

  Deeks, Steven G ^a   Odorizzi, Pamela M ^a   Sekaly, Rafick Pierre ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; INTERFERON; ANTIRETROVIRUS AGENT;

ANTIVIRAL THERAPY; DRUG MECHANISM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNITY; LIFESPAN; NONHUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; ANIMAL; DISEASE MODEL; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; MOUSE;

ANIMALS; ANTI-RETROVIRAL AGENTS; DISEASE MODELS, ANIMAL; HIV INFECTIONS; HIV-1; HUMANS; INTERFERON TYPE I; MICE;

EID: 85008384523     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI91916     Document Type: Review

References (24)

1. Deeks SG, et al. International AIDS Society global scientific strategy: towards an HIV cure 2016. Nat Med. 2016;22(8):839-850.
2. Sandler NG, et al. Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression. Nature. 2014;511(7511):601-605.
3. Hardy GA, et al. Interferon-α is the primary plasma type-I IFN in HIV-1 infection and correlates with immune activation and disease markers. PLoS One. 2013;8(2):e56527.
4. Favre D, et al. Tryptophan catabolism by indoleamine 2, 3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease. Sci Transl Med. 2010;2(32):32-36.
5. Le Saout C, et al. Chronic exposure to type-I IFN under lymphopenic conditions alters CD4 T cell homeostasis. PLoS Pathog. 2014;10(3):e1003976.
6. Fernandez S, et al. CD4+ T-cell deficiency in HIV patients responding to antiretroviral therapy is associated with increased expression of interferon- stimulated genes in CD4+ T cells. J Infect Dis. 2011;204(12):1927-1935.
7. Dunham RM, et al. Discordance between peripheral and colonic markers of inflammation during suppressive ART. J Acquir Immune Defic Syndr. 2014;65(2):133-141.
8. Tenorio AR, et al. Soluble markers of inflammation and coagulation, but not T-cell activation, are predictors of non-AIDS-defining morbid events during suppressive antiretroviral treatment. J Infect Dis. 2014;210(8):1248-1259.
9. Hunt PW, et al. Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection. J Infect Dis. 2014;210(8):1228-1238.
10. Lederman MM, et al. Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells. J Infect Dis. 2011;204(8):1217-1226.
11. Catalfamo M, et al. CD4 and CD8 T cell immune activation during chronic HIV infection: roles of homeostasis, HIV, type I IFN, and IL-7. J Immunol. 2011;186(4):2106-2116.
12. Mudd JC, et al. Impaired T-cell responses to sphingosine-1-phosphate in HIV-1 infected lymph nodes. Blood. 2013;121(15):2914-2922.
13. Manion M, et al. Interferon-alpha administration enhances CD8+ T cell activation in HIV infection. PLoS One. 2012;7(1):e30306.
14. Stoddart CA, Keir ME, McCune JM. IFN- α-induced upregulation of CCR5 leads to expanded HIV tropism in vivo. PLoS Pathog. 2010;6(2):e1000766.
15. Odorizzi PM, Wherry EJ. Immunology. Science. 2013;340(6129):155-156.
16. Wilson EB, et al. Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science. 2013;340(6129):202-207.
17. Teijaro JR, et al. Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science. 2013;340(6129):207-211.
18. Zhen A, et al. Targeting type I interferon- mediated activation restores immune function in chronic HIV infection. J Clin Invest. 2017;127(1):260-268.
19. Cheng L, et al. Blocking type I interferon signaling enhances T cell recovery reduces HIV-1 reservoirs. J Clin Invest. 2017;127(1):269-279.
20. Klatt NR, Chomont N, Douek DC, Deeks SG. Immune activation and HIV persistence: implications for curative approaches to HIV infection. Immunol Rev. 2013;254(1):326-342.
21. Katlama C, et al. Barriers to a cure for HIV: newways to target and eradicate HIV-1 reservoirs. Lancet. 2013;381(9883):2109-2117.
22. Oon S, Wilson NJ, Wicks I. Targeted therapeutics in SLE: emerging strategies to modulate the interferon pathway. Clin Transl Immunology. 2016;5(5):e79.
23. Kalunian KC, et al. A phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE). Ann Rheum Dis. 2016;75(1):196-202.
24. Khamashta M, et al. Sifalimumab, an anti-interferon- α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016;75(11):1909-1916.